AI Adoption Is Advancing—But Not in the Way the Market Narrative Suggests The 2026 State of Validation study shows that AI is no longer speculative in validation and quality environments. Nearly 40% of respondents report that their organizations are already using or actively evaluating AI in GxP settings, and a clear majority expect AI to become standard practice within the decade. As adoption expands, the study also underscores the need for AI governance in validation and c

Paper Hasn’t Disappeared—It’s Coexisting The 2026 State of Validation study confirms what many quality teams already experience day to day: despite steady investment in digital validation tools, paper remains embedded in paper-based GxP records. More than 30% of respondents report that validation protocols are still primarily paper‑based, alongside logbooks and batch records. This places many organizations squarely in hybrid validation environments, where paper and digital

The Digital Validation ROI Question Is No Longer Theoretical The 2026 State of Validation study reports that organizations investing in digital validation are, in most cases, seeing a return. Nearly three‑quarters of respondents with implemented or in‑progress systems reported that ROI met or exceeded expectations, with more than half indicating that returns surpassed initial projections. At first glance, this appears to settle a long‑standing debate about whether digital v

The U.S. Food and Drug Administration recently announced two developments that, taken together, mark a meaningful shift in how the agency is operationalizing artificial intelligence (AI) at the FDA: an expansion of its internal AI capabilities and the completion of a long‑running effort to consolidate FDA data systems into a unified platform. This announcement was framed as infrastructure—not as a new policy or regulatory position. That distinction matters. From FDA AI pilo

As real‑time clinical trials gain regulatory traction, documentation expectations are evolving—not disappearing. This analysis explains why regulatory records persist and how sponsors should plan accordingly.

“Integration” has become a catch-all term in conversations about compliant AI deployments in pharma, secure clinical documentation platforms, and audit-ready AI workflows. Too often, it is used to describe surface-level connectivity—systems exchanging files or triggering downstream actions—rather than true workflow integration. In regulated writing environments, this distinction matters. Identity, versioning, traceability, and review context are not conveniences; they are le

Join Synterex leadership for "CTIS, Plain Language Summaries, and Accessibility at Scale," a webinar about governed agentic AI on May 6, at 11:00am ET.

In medical and regulatory writing workflows, discussions about AI often default to speed—draft faster, iterate faster, review faster. From the perspective of regulatory reviewers, however, speed alone rarely improves outcomes. Reviewers are responsible for evaluating safety, efficacy, and scientific integrity, and those responsibilities depend far more on context, traceability, and confidence than on how quickly a document was produced. Reframing AI’s role around the reviewe

Regulatory review has traditionally been treated as a discrete phase—an endpoint where documents move from creation to evaluation, often triggering compressed timelines and late-stage rework. In practice, regulatory decisions are rarely made at a single moment. They emerge gradually, as evidence, context, and interpretation come into focus. Regulatory review automation enabled by AI does not replace this process or accelerate decisions indiscriminately. Instead, it reshapes

AI hallucinations are often described as unpredictable failures—or as evidence that generative AI can’t be trusted in regulated environments. That interpretation is understandable, but incomplete. In reality, hallucinations occur because large language models generate text based on probability, not verification. They are a predictable result of how AI systems express confidence when certainty is unavailable. Once that’s understood, hallucinations become easier to anticipate

As life sciences organizations race to adopt AI-powered regulatory documentation, a critical distinction is often blurred: AI can accelerate execution, but it cannot replace thinking. What it can do—exceptionally well—is scale whatever clarity or confusion already exists upstream. AI does not decide what a regulatory narrative should be. It reflects how well that narrative has been designed. Before organizations automate regulatory writing, they must first invest in clari